Cutler Group LP Affimed N.V. Call Options Transaction History

Cutler Group LP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 07, 2023	SELL	$1.1 - $2.45 $3,850 - $8,575	-3,500 Reduced 67.31%	1,700 $0
Q3 2022 Oct 25, 2022	BUY	$1.96 - $3.32 $1,764 - $2,988	900 Added 20.93%	5,200 $0
Q2 2022 Aug 04, 2022	BUY	$2.27 - $4.86 $9,761 - $20,898	4,300 New	4,300 $1,000
Q1 2022 Apr 14, 2022	SELL	$3.69 - $5.65 $51,291 - $78,535	-13,900 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$5.37 - $7.07 $73,032 - $96,152	13,600 Added 4533.33%	13,900 $1,000
Q3 2021 Oct 26, 2021	SELL	$5.54 - $7.51 $12,742 - $17,273	-2,300 Reduced 88.46%	300 $0
Q2 2021 Jul 19, 2021	SELL	$7.78 - $11.4 $11,670 - $17,100	-1,500 Reduced 36.59%	2,600 $0
Q3 2018 Nov 07, 2018	BUY	$1.45 - $6.15 $5,945 - $25,215	4,100 New	4,100 $0

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.